<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02449941</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0341</org_study_id>
    <nct_id>NCT02449941</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori and Proton Pump Inhibitor</brief_title>
  <official_title>Distribution of Helicobacter Pylori According to the Use of Proton Pump Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to know the distribution of HP in stomach before use of PPI,
      during use of PPI, and after stop of PPI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopy and biopsy will be performed to investigate the distrubition of HP before, during,
      and after using PPI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis the change of Helicobacter pylori distribution according to the use of proton pump inhibitor</measure>
    <time_frame>Change in the distribution of Helicobacter Pylori(HP) at 4 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis the change of HP distribution according to the use of PPI in atrophic change of stomach</measure>
    <time_frame>Change in the distribution of Helicobacter Pylori(HP) at 4 months.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Helicobacter Infections</condition>
  <arm_group>
    <arm_group_label>Helicobacter pylori(HP) positive</arm_group_label>
    <description>Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPI (proton pump inhibitor)</intervention_name>
    <description>Pre ESD (endoscopic submucosal dissection)
Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori
Use of PPI for 2 months
Post ESD 1 (After 2 months)
Assess the distribution of helicobacter pylori after using PPI.
Stop of PPI
Post ESD 2 (After 4 months)
Assess the distribution of helicobacter pylori after stop of PPI.</description>
    <arm_group_label>Helicobacter pylori(HP) positive</arm_group_label>
    <other_name>pantoprazole, lansoprazole, dexlansoprazole, rabeprazole</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      endoscopic biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Sample size will be determined based on the analysis the distribution rate of HP at first
        30 patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who are indicated to endoscopic resection due to gastric neoplasm

          2. Aged between 19 to 65 years

          3. Informed consent

        Exclusion Criteria:

          1. Previous history of HP eradication

          2. Previous history of PPI use within 6 months

          3. No HP infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Yong Ahn, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2015</study_first_posted>
  <last_update_submitted>December 4, 2016</last_update_submitted>
  <last_update_submitted_qc>December 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Ji Yong Ahn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Stomach Neoplasms</keyword>
  <keyword>proton pump inhibitor</keyword>
  <keyword>endoscopic submucosal dissection</keyword>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Gastritis, Atrophic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

